Creating organoid cultures from male breast tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish organoid cultures derived from male breast cancer patients who have undergone surgery. The project will generate at least five organoid cultures to assess their success rate and verify their correspondence with the original tumor tissue. Comprehensive molecular investigations, including DNA mutational analysis, RNA sequencing, and proteomic studies, will be conducted to understand the underlying mechanisms of the tumor. Additionally, in vitro viability tests will evaluate the organoids' response to the same treatments given to the patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men aged \>18 years
* Patients with histologically confirmed breast cancer with or without synchronous metastases, who will undergo the relevant surgical intervention
* Adequate biological material to be able to carry out the analyses described above
* Signing of the relevant informed consent form

Exclusion Criteria:

not present

Where it's running

• IRCCS National Cancer Institute "Regina Elena"
  Rome, Italy Recruiting

Study contacts

• Study coordinator: Giovanni Blandino, Medical Doctor
• Email: giovanni.blandino@ifo.it
• Phone: +39 0652662911

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Male Breast Cancer Predisposition Factor: Create a Control Group

  This study tests genetic and psychosocial data in men who are relatives of men with breast cancer but who themselves have no cancer history.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07558343

• Treatment for male breast cancer using endocrine therapy

  This study is testing different combinations of hormone therapy for men with early to mid-stage breast cancer to see which one works best compared to the usual treatment.

  Recruiting at 9 sites Phase 2 Dana-Farber Cancer Institute · Washington D.C., District of Columbia and 8 other locations · NCT05501704

• Improving access to genetic testing for underserved cancer patients

  This study is testing whether a computer character can give better information about genetic testing to underserved cancer patients compared to regular human healthcare providers.

  Recruiting at 2 sites University of Southern California · Los Angeles, California and 1 other locations · NCT06422455

• Assessing safety of combining radiotherapy with new systemic therapies for breast cancer

  This study is testing if it's safe to give new breast cancer treatments together with radiation therapy to see if they can work well together for patients who need both.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06197581

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.